Abstract:Objective To compare the neuromuscular blocking effects of rocuronium given by intermittent bolus injection, continuous infusion and target-controlled infusion during liver transplantation. Methods Thirty-six patients with hepatic failure of both sexes aged 21-63 yr weighing 48-80 kg undergoing liver transplantation were studied. The donor livers were obtained from living donors. The patients were divided into 3 groups according to the mode of rocuronium administration ( n = 12 each): group Ⅰ intermittent bolus injection (group Ⅳ); group Ⅱ continuous infusion (group CI) and group Ⅲ target-controlled infusion (group TCI). Neuromuscular block was assessed by TOF stimulation of ulnar nerve (TOF-Watch SX). Anesthesia was induced with midazolam 5 mg,fentanyl 4-6 μg/kg and propofol 1.0-1.5 mg/kg, and rocuronium was administered using different modes of administration. A bolus of rocuronium 0.6 mg/kg was given during induction and supplemental rocuronium 0.15 mg/kg was given when T1 was returned to 25% in preanhepatic stage and T4/T1 (TOFR) returned to 25% in anhepatic and neohepatic stages in group Ⅳ. TCI at an initial target effect-site concentration of 3 μg/ml was started during induction, the concentration was adjusted to maintain T1 at 5%-10% , TCI was temporarily suspended at the beginning of anhepatic and neohepatic stages, and then TCI at a target effect-site concentration of 0.1 μg/ml was started again and the concentration was adjusted to maintain T1 at 5%-10% in group TCI. A bolus of rocuronium 0.6 mg/kg was given during induction, the initial infusion rate was set at 30 μg· kg-1 ·min-1 and then adjusted to maintain T1 at 5%-10% in preanhepatic stage, CI was temporarily suspended at the beginning of anhepatic and neohepatic stages, and then it was started again at 1 μg· kg-1 · min-1 in preanhepatic stage and the infusion rate was adjusted to maintain T1 at 5%-10% in group CI. Tracheal intubation was performed when the maximal effect was achieved. The administration was stopped after suture of the peritoneum. The onset time, the maximal depression of T1 , intubation condition, recovery time and the total amount of rocuronium consumed were recorded.Results There was no significant difference in onset time, the maximal depression of T1, intubation condition,ecovery time and the total amount of rocuronium consumed among the 3 groups ( P ＞ 0.05). Conclusion There is no significant difference in the onset and recovery when neuromuscular blocade was induced by rocuronium via Ⅳ, CI and TCI, but neuromuscular blockade induced by rocuronium via TCI and CI is more stable than that induced by rocuronium via Ⅳ during liver transplantation.

Rocuronium bromide and organ function

Is neuromuscular relaxation of rocuronium prolonged in patients with obstructive jaundice?

The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis

Pharmacodynamics of Rocuronium in Cholestatic Patients with or Without Hepatocellular Injury: Normal Onset Time of Initial Dose and Prolonged Duration Time after Repeated Doses

Prolonged onset and duration of action of rocuronium after accidental subcutaneous injection in a patient with chronic renal failure—a case report

Metabolic pathway of rocuronium in patients with end-stage liver disease

Increased Renal Clearance of Rocuronium Compensates for Chronic Loss of Bile Excretion, via upregulation of Oatp2

Rocuronium Has a Suppressive Effect on Platelet Function via the P2Y12 Receptor Pathway In Vitro That Is Not Reversed by Sugammadex

Influence of Obstructive Jaundice on Pharmacodynamics of Rocuronium

Comparison of Neuromuscular Blocking Effects of Rocuronium Given by Different Methods of Administration During Liver Transplantation

Relationship Between Hepatic Potential Capacity and the Pharmcodynamics of Rocuronium

Influence of Age on the Recovery of Neuromuscular Function after Continuous Infusion of Rocuronium Bromide

Risk of Acute Complications with Rocuronium versus Cisatracurium in Patients with Chronic Kidney Disease: A Propensity-Matched Study

The Effect of Patient Weight and Provider Training and Experience on Dosing of Rocuronium

Effects of Skeletal Muscle Denervation on Potency of Rocuronium

Navigating Anesthesia: Muscle Relaxants and Reversal Agents in Patients with Renal Impairment

Rocuronium exacerbates mechanical ventilation-induced diaphragm dysfunction in rats

Rocuronium Reversal in the Emergency Department: Retrospective Evaluation of Hemodynamic Instability Following Administration of Sugammadex Versus Neostigmine With Glycopyrrolate

Efficacy and Safety of Sugammadex for the Reversal of Rocuronium-Induced Neuromuscular Blockade in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis

Effects of Arterial Carbon Dioxide on Recovery from Rocuronium-Induced Neuromuscular Blockade in Anesthetized Patients

Effects of Dexmedetomidine on the Onset and Duration of Action in Non-Depolarizing Neuromuscular Relaxant Rocuronium